Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.tp.0000147463.92625.14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastric Accommodation Testing Using Hybrid Nuclear Imaging Volumetry and Combined High-Resolution Manometry-Nutrient Drink Test: A Pilot Study in Healthy Individuals.
Neurogastroenterol Motil
January 2025
Department of Nuclear Medicine, Radiotherapy & Oncology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kota Bharu, Kelantan, Malaysia.
Background: Gastric accommodation (GA) testing is gaining clinical recognition as novel and minimally invasive modalities emerge. We investigated the feasibility of hybrid nuclear imaging volumetry (SPECT/CT) and combined high-resolution manometry-nutrient drink test (HRM-NDT) to assess GA.
Methods: In this non-randomized pilot study, [Tc]NaTcO gastric SPECT/CT (250 mL protocol) and proximal gastric HRM-NDT (~60 mL/min protocol) were performed separately within 30 days using Ensure Gold test meal (1.
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
BMC Cancer
January 2025
Barts Cancer Institute and Wolfson Institute of Public Health, Mary University of London, John Vane Science Centre, Charterhouse Square, London, Queen, EC1M 6BQ, UK.
Background: Pancreatic cancer (PDAC: pancreatic ductal adenocarcinoma, the commonest form), a lethal disease, is best treated with surgical excision but is feasible in less than a fifth of patients. Around a third of patients presentlocally advanced, inoperable, non-metastatic (laPDAC), whose stadrd of care is palliative chemotherapy; a small minority are down-sized sufficiently to enable surgical excision. We propose a phase II clinical trial to test whether a combination of standard chemotherapy (gemcitabine & nab-Paclitaxel: GEM-NABP) and repurposing All Trans Retinoic Acid (ATRA) to target the stroma may extend progression-free survival and enable successful surgical resection for patients with laPDAC, since data from phase IB clinical trial demonstrate safety of GEM-NABP-ATRA combination to patients with advanced PDAC with potential therapeutic benefit.
View Article and Find Full Text PDFEnvironmental Challenges and Co-Infection Modulate Resistance and Tolerance Against Trypanosoma Cruzi and Trichinella Spiralis in Rats.
J Exp Zool A Ecol Integr Physiol
January 2025
Laboratorio de Ecología de Enfermedades, Instituto de Ciencias Veterinarias del Litoral (ICIVET LITORAL), Universidad Nacional del Litoral - CONICET, Santa Fe, Santa Fe, Argentina.
To overcome infection, hosts employ two defense strategies: resistance (which limits pathogen fitness), and tolerance (which reduces infection damage). These strategies may be influenced by environmental challenges such as food shortage, social conflict, and co-infections. Here, our objective was to assess defense strategies in rats infected with Trichinella spiralis and/or Trypanosoma cruzi under environmental challenges.
View Article and Find Full Text PDFA sequential Au(I)/TBAF-promoted rapid and selective functionalization of heteroarene -oxides with alkynes.
Chem Commun (Camb)
January 2025
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
We present a rapid and versatile Au(I)-catalyzed strategy for functionalizing N-heteroarenes using TBAF as a nucleophile or base, enabling varied transformations. The method accommodates diverse substrates, offering excellent yields and functional group tolerance. Distinct reaction pathways highlight its adaptability, expanding chemical diversity for organic synthesis.
View Article and Find Full Text PDFEfficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Eur J Cancer
January 2025
Department of Gynecology with Breast Unit, Charité Hospital Berlin, Germany; Interdisciplinary Breast Unit, Kliniken Essen Mitte, Essen, Germany.
Background: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC). We report efficacy, safety, and patient-reported outcomes (PROs) across age groups, including older patients, in these trials.
Methods: Data from the MONALEESA-2, -3, and -7 trials for pre- and postmenopausal patients receiving first-line treatment for ABC were pooled and analyzed by age (<65y, 65-74y, and ≥75y).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!